GB8904161D0
(en)
*
|
1989-02-23 |
1989-04-05 |
Hoffmann La Roche |
Substituted pyrroles
|
MC2096A1
(fr)
*
|
1989-02-23 |
1991-02-15 |
Hoffmann La Roche |
Pyrroles substitues
|
US5380746A
(en)
*
|
1989-05-05 |
1995-01-10 |
Goedecke Aktiengesellschaft |
Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
|
PT93947B
(pt)
*
|
1989-05-05 |
1996-11-29 |
Goedecke Ag |
Processo para a preparacao de novos derivados de maleinimidas e de composicoes farmaceuticas que os contem
|
DE3914764A1
(de)
*
|
1989-05-05 |
1990-11-08 |
Goedecke Ag |
Maleinimid-derivate und deren verwendung als arzneimittel
|
DE4005970A1
(de)
*
|
1990-02-26 |
1991-08-29 |
Boehringer Mannheim Gmbh |
Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
|
DE4005969A1
(de)
*
|
1990-02-26 |
1991-08-29 |
Boehringer Mannheim Gmbh |
Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
|
CA2046801C
(en)
*
|
1990-08-07 |
2002-02-26 |
Peter D. Davis |
Substituted pyrroles
|
US5292747A
(en)
*
|
1990-08-07 |
1994-03-08 |
Hoffman-La Roche Inc. |
Substituted pyrroles
|
GB9123396D0
(en)
*
|
1991-11-04 |
1991-12-18 |
Hoffmann La Roche |
A process for the manufacture of substituted maleimides
|
EP0630241A1
(en)
*
|
1992-03-20 |
1994-12-28 |
The Wellcome Foundation Limited |
Indole derivatives with antiviral activity
|
US5290777A
(en)
*
|
1993-02-24 |
1994-03-01 |
Regents Of The Univ. Of California |
Use for topsentin compounds and pharmaceutical compositions containing same
|
US5721230A
(en)
*
|
1993-05-10 |
1998-02-24 |
Hoffmann-La Roche Inc. |
Substituted pyrroles
|
AU678435B2
(en)
*
|
1993-05-10 |
1997-05-29 |
F. Hoffmann-La Roche Ag |
Substituted pyrroles
|
US5405864A
(en)
*
|
1993-10-15 |
1995-04-11 |
Syntex (U.S.A.) Inc. |
Chemotherapeutic maleimides
|
TW270114B
(no)
*
|
1993-10-22 |
1996-02-11 |
Hoffmann La Roche |
|
ATE204579T1
(de)
*
|
1993-12-07 |
2001-09-15 |
Lilly Co Eli |
Proteinkinase c-inhibitoren
|
US5843935A
(en)
*
|
1993-12-07 |
1998-12-01 |
Eli Lilly And Company |
Protein kinase C inhibitors
|
US5624949A
(en)
*
|
1993-12-07 |
1997-04-29 |
Eli Lilly And Company |
Protein kinase C inhibitors
|
US5723456A
(en)
*
|
1993-12-07 |
1998-03-03 |
Eli Lilly & Company |
Therapeutic treatment for cardiovascular diseases
|
FI945705A
(fi)
*
|
1993-12-07 |
1996-06-03 |
Lilly Co Eli |
Bisindolyylimaleimidien parannettu synteesi
|
US5541347A
(en)
*
|
1993-12-07 |
1996-07-30 |
Eli Lilly And Company |
Synthesis of bisindolylmaleimides
|
ATE290378T1
(de)
|
1993-12-23 |
2005-03-15 |
Lilly Co Eli |
Proteinkinase c-inhibitoren
|
US5545636A
(en)
*
|
1993-12-23 |
1996-08-13 |
Eli Lilly And Company |
Protein kinase C inhibitors
|
AU2771395A
(en)
*
|
1994-06-14 |
1996-01-05 |
Sloan-Kettering Institute For Cancer Research |
Ceramide-activated protein kinase and methods of use of effectors
|
US5481003A
(en)
*
|
1994-06-22 |
1996-01-02 |
Eli Lilly And Company |
Protein kinase C inhibitors
|
US5491242A
(en)
*
|
1994-06-22 |
1996-02-13 |
Eli Lilly And Company |
Protein kinase C inhibitors
|
ES2123873T3
(es)
*
|
1994-08-04 |
1999-01-16 |
Hoffmann La Roche |
Pirrolocarbazol.
|
US5594009A
(en)
*
|
1994-10-14 |
1997-01-14 |
Cephalon, Inc. |
Fused pyrrolocarbazoles
|
US5475110A
(en)
*
|
1994-10-14 |
1995-12-12 |
Cephalon, Inc. |
Fused Pyrrolocarbazoles
|
US5705511A
(en)
*
|
1994-10-14 |
1998-01-06 |
Cephalon, Inc. |
Fused pyrrolocarbazoles
|
US5591855A
(en)
*
|
1994-10-14 |
1997-01-07 |
Cephalon, Inc. |
Fused pyrrolocarbazoles
|
US5559228A
(en)
*
|
1995-03-30 |
1996-09-24 |
Eli Lilly And Company |
Synthesis of bisindolylmaleimides
|
WO1997009339A1
(fr)
*
|
1995-09-05 |
1997-03-13 |
Banyu Pharmaceutical Co., Ltd. |
Derives antitumoraux d'indolopyrrolocarbazole
|
CA2237221C
(en)
*
|
1995-11-20 |
2003-03-25 |
Eli Lilly And Company |
Protein kinase c inhibitor
|
US5616724A
(en)
*
|
1996-02-21 |
1997-04-01 |
Cephalon, Inc. |
Fused pyrrolo[2,3-c]carbazole-6-ones
|
EP0888339A4
(en)
*
|
1996-03-20 |
2001-02-28 |
Lilly Co Eli |
SYNTHESIS OF INDOLYLMALEINIMIDES
|
JP2002504086A
(ja)
|
1996-05-01 |
2002-02-05 |
イーライ・リリー・アンド・カンパニー |
Vegf関連疾患の治療的処置
|
UA54427C2
(uk)
*
|
1996-05-01 |
2003-03-17 |
Елі Ліллі Енд Компані |
Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
|
US6232299B1
(en)
|
1996-05-01 |
2001-05-15 |
Eli Lilly And Company |
Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
|
PE91498A1
(es)
*
|
1996-07-29 |
1998-12-22 |
Hoffmann La Roche |
Pirroles sustituidos
|
PE91698A1
(es)
*
|
1996-07-29 |
1998-12-24 |
Hoffmann La Roche |
Pirroles sustituidos
|
PE91598A1
(es)
|
1996-07-29 |
1998-12-24 |
Hoffmann La Roche |
Pirroles sustituidos
|
US6093709A
(en)
*
|
1996-08-22 |
2000-07-25 |
Eli Lilly And Company |
Therapeutic treatment for sexual dysfunctions
|
EA001392B1
(ru)
*
|
1996-08-23 |
2001-02-26 |
Эли Лилли Энд Компани |
Синтез бисиндолилмалеимидов
|
US5962446A
(en)
*
|
1996-08-30 |
1999-10-05 |
Eli Lilly And Company |
Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
|
US6107327A
(en)
*
|
1996-08-30 |
2000-08-22 |
Eli Lilly And Company |
Therapeutic treatment for HIV infection
|
SE9603283D0
(sv)
*
|
1996-09-10 |
1996-09-10 |
Astra Ab |
New compounds
|
SE9603284D0
(sv)
*
|
1996-09-10 |
1996-09-10 |
Astra Ab |
New compounds
|
TW472045B
(en)
*
|
1996-09-25 |
2002-01-11 |
Astra Ab |
Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
|
CA2268399C
(en)
*
|
1996-10-31 |
2008-08-19 |
Harbor Branch Oceanographic Institution, Inc. |
Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
|
US5859261A
(en)
*
|
1997-03-20 |
1999-01-12 |
Eli Lilly And Company |
Synthesis of indolylmaleimides
|
US6093740A
(en)
*
|
1997-04-30 |
2000-07-25 |
Eli Lilly And Company |
Therapeutic treatment for skin disorders
|
US6133452A
(en)
*
|
1997-08-22 |
2000-10-17 |
Eli Lilly And Company |
Synthesis of bisindolylmalimides
|
AR017200A1
(es)
|
1997-12-23 |
2001-08-22 |
Astrazeneca Ab |
Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
|
EP1057484A4
(en)
*
|
1998-02-23 |
2002-11-20 |
Sagami Chem Res |
INHIBITORS OF CELL DEATH
|
US6225301B1
(en)
|
1998-03-05 |
2001-05-01 |
Eli Lilly And Company |
Therapeutic treatment for renal dysfunction
|
US6291446B1
(en)
|
1998-03-05 |
2001-09-18 |
Eli Lilly And Company |
Therapeutic treatment for cytomegalovirus infection
|
US6103712A
(en)
*
|
1998-03-05 |
2000-08-15 |
Eli Lilly And Company |
Therapeutic treatment for asthma
|
US6103713A
(en)
*
|
1998-03-05 |
2000-08-15 |
Eli Lilly And Company |
Therapeutic treatment for autoimmune diseases
|
SE9800835D0
(sv)
|
1998-03-13 |
1998-03-13 |
Astra Ab |
New Compounds
|
RS49965B
(sr)
*
|
1998-03-17 |
2008-09-29 |
F.Hoffmann-La Roche Ag., |
Supstituisani bisindolmaleimidi za inhibiciju ćelijske proliferacije
|
SE9802538D0
(sv)
*
|
1998-07-13 |
1998-07-13 |
Astra Ab |
New pharmaceutically active compounds
|
US6350786B1
(en)
*
|
1998-09-22 |
2002-02-26 |
Hoffmann-La Roche Inc. |
Stable complexes of poorly soluble compounds in ionic polymers
|
US6719520B2
(en)
|
1998-10-08 |
2004-04-13 |
Smithkline Beecham Corporation |
Method and compounds
|
JP2002527419A
(ja)
*
|
1998-10-08 |
2002-08-27 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
Gsk−3阻害物質としてのピロール−2,5−ジオン類
|
GB9828640D0
(en)
*
|
1998-12-23 |
1999-02-17 |
Smithkline Beecham Plc |
Novel method and compounds
|
PT1165558E
(pt)
*
|
1999-03-31 |
2004-02-27 |
Vernalis Ltd |
Derivados de pirimido¬6,1-a|isoquinolina-4-ona
|
US6492406B1
(en)
|
1999-05-21 |
2002-12-10 |
Astrazeneca Ab |
Pharmaceutically active compounds
|
US6284783B1
(en)
|
1999-06-09 |
2001-09-04 |
The Uab Research Foundation |
Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
|
US6346625B1
(en)
|
1999-06-23 |
2002-02-12 |
Astrazeneca Ab |
Protein kinase inhibitors
|
WO2001013916A1
(fr)
*
|
1999-08-20 |
2001-03-01 |
Sagami Chemical Research Center |
Medicaments inhibant la mort cellulaire
|
US6559164B1
(en)
|
1999-10-12 |
2003-05-06 |
Hoffmann-La Roche Inc. |
Substituted pyrroles suitable for continuous infusion
|
US6313143B1
(en)
*
|
1999-12-16 |
2001-11-06 |
Hoffmann-La Roche Inc. |
Substituted pyrroles
|
US6281356B1
(en)
|
1999-12-22 |
2001-08-28 |
Hoffmann-La Roche Inc. |
Substituted pyrroles
|
GB0008264D0
(en)
*
|
2000-04-04 |
2000-05-24 |
Smithkline Beecham Plc |
Novel method and compounds
|
US6326501B1
(en)
*
|
2000-04-19 |
2001-12-04 |
Hoffmann-La Roche Inc. |
Methylation of indole compounds using dimethyl carbonate
|
CA2308994A1
(en)
*
|
2000-05-19 |
2001-11-19 |
Aegera Therapeutics Inc. |
Neuroprotective compounds
|
US7129250B2
(en)
*
|
2000-05-19 |
2006-10-31 |
Aegera Therapeutics Inc. |
Neuroprotective and anti-proliferative compounds
|
US6353007B1
(en)
*
|
2000-07-13 |
2002-03-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents
|
DE60107857T2
(de)
*
|
2000-07-27 |
2005-12-08 |
F. Hoffmann-La Roche Ag |
3-Indolyl-4-Phenyl-1H-Pyrrol-2,5-Dion-Derivate als Glycogen Synthase-Kinase 3Beta Inhibitoren
|
US6469179B1
(en)
*
|
2000-10-03 |
2002-10-22 |
Hoffmann-La Roche Inc. |
Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
|
US6482847B2
(en)
*
|
2000-10-03 |
2002-11-19 |
Hoffmann-La Roche Inc. |
Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
|
KR100916613B1
(ko)
*
|
2000-11-07 |
2009-09-14 |
노파르티스 아게 |
단백질 키나제 c 억제제로서의 인돌릴말레이미드 유도체
|
US6645970B2
(en)
|
2000-11-07 |
2003-11-11 |
Novartis Ag |
Indolylmaleimide derivatives
|
US6849643B2
(en)
*
|
2000-12-08 |
2005-02-01 |
Ortho-Mcneil Pharmaceutical, Inc. |
Indazolyl-substituted pyrroline compounds as kinase inhibitors
|
US6548531B2
(en)
|
2001-02-09 |
2003-04-15 |
Hoffmann-La Roche Inc. |
Method for cancer therapy
|
DE10109280A1
(de)
*
|
2001-02-26 |
2002-09-05 |
Peter Mayser |
Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
|
WO2002102373A1
(en)
*
|
2001-06-15 |
2002-12-27 |
F. Hoffmann-La Roche Ag |
Method for administration of cancer therapeutic
|
TW201041580A
(en)
|
2001-09-27 |
2010-12-01 |
Alcon Inc |
Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
|
EP1441772A2
(en)
*
|
2001-10-29 |
2004-08-04 |
Nektar Therapeutics Al, Corporation |
Polymer conjugates of protein kinase c inhibitors
|
US20030139373A1
(en)
*
|
2001-11-20 |
2003-07-24 |
Breimer Lars Holger |
Method for cancer therapy
|
PT1483265E
(pt)
*
|
2002-03-05 |
2007-01-31 |
Lilly Co Eli |
Derivados de purina como inibidores de quinase
|
DE60315270T2
(de)
*
|
2002-03-08 |
2008-04-17 |
Eli Lilly And Co., Indianapolis |
Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren
|
TW200918046A
(en)
|
2002-04-03 |
2009-05-01 |
Novartis Ag |
Indolylmaleimide derivatives
|
EP1900738A3
(en)
*
|
2002-05-08 |
2008-04-09 |
Janssen Pharmaceutica, N.V. |
Substituted pyrroline kinase inhibitors
|
DE60319364T2
(de)
*
|
2002-05-08 |
2009-02-19 |
Janssen Pharmaceutica N.V. |
Substituierte pyrroline als kinase inhibitoren
|
ES2312785T3
(es)
*
|
2002-06-05 |
2009-03-01 |
Janssen Pharmaceutica Nv |
Pirrolinas sustituidas utiles como inhibidores de quinasa.
|
CA2488602A1
(en)
|
2002-06-05 |
2003-12-18 |
Janssen Pharmaceutica N.V. |
Substituted pyrrolines as kinase inhibitors
|
CA2393720C
(en)
*
|
2002-07-12 |
2010-09-14 |
Eli Lilly And Company |
Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
|
US6800655B2
(en)
*
|
2002-08-20 |
2004-10-05 |
Sri International |
Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
|
GB0303319D0
(en)
*
|
2003-02-13 |
2003-03-19 |
Novartis Ag |
Organic compounds
|
EP1611132A1
(en)
*
|
2003-03-27 |
2006-01-04 |
Janssen Pharmaceutica N.V. |
Substituted pyrroline kinase inhibitors
|
CN1832940A
(zh)
*
|
2003-06-13 |
2006-09-13 |
詹森药业有限公司 |
用作激酶抑制剂的取代的吲唑基(吲哚基)马来酰亚胺衍生物
|
CN100536850C
(zh)
|
2003-08-08 |
2009-09-09 |
诺瓦提斯公司 |
包含星孢素的组合
|
US7691861B2
(en)
*
|
2004-01-19 |
2010-04-06 |
Novartis Ag |
Indolymaleimide derivatives
|
JP2007532506A
(ja)
*
|
2004-04-08 |
2007-11-15 |
ノバルティス アクチエンゲゼルシャフト |
自己免疫疾患および拒絶反応の処置のためのタンパク質キナーゼc阻害剤
|
JP2008504292A
(ja)
|
2004-06-24 |
2008-02-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
免疫増強用の化合物
|
EP1819697B1
(en)
*
|
2004-12-08 |
2012-08-01 |
Johannes Gutenberg-Universität Mainz |
3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
|
JP2008526750A
(ja)
*
|
2005-01-04 |
2008-07-24 |
ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ |
脳血流を増加させる方法
|
RU2547148C2
(ru)
*
|
2005-02-09 |
2015-04-10 |
Аркьюл, Инк. |
Композиции и способы лечения рака
|
WO2007006533A2
(en)
*
|
2005-07-11 |
2007-01-18 |
Novartis Ag |
Indolylmaleimide derivatives
|
WO2007027974A1
(en)
*
|
2005-09-02 |
2007-03-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method for reducing risk of and extent of injury due to stroke in hypertensive subjects
|
US20070112053A1
(en)
|
2005-09-16 |
2007-05-17 |
Pickett Cecil B |
Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
|
EP2125683B1
(en)
*
|
2006-12-19 |
2013-10-23 |
The Board of Trustees of the University of Illinois |
3-benzofuranyl-4-indolyl-maleimides as potent gsk-3 inhibitors for neurodegenerative disorders
|
EP2173748B1
(en)
*
|
2007-06-22 |
2011-08-31 |
ArQule, Inc. |
Indolyl pyrrolidines for the treatment of cancer
|
JP2010530885A
(ja)
*
|
2007-06-22 |
2010-09-16 |
アークル インコーポレイテッド |
キナゾリノン化合物およびその使用方法
|
JP5425060B2
(ja)
*
|
2007-06-22 |
2014-02-26 |
アークル インコーポレイテッド |
ピロリジノン、ピロリジン−2,5−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
|
FR2927075A1
(fr)
*
|
2008-02-04 |
2009-08-07 |
Centre Nat Rech Scient |
Molecules comprenant un squelette bis-(heteroaryl)maleimide, et leur utilisation dans l'inhibition d'enzymes
|
US8304421B2
(en)
*
|
2008-09-30 |
2012-11-06 |
Vanderbilt University |
Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
|
EP2338486A1
(en)
|
2009-12-18 |
2011-06-29 |
Johannes Gutenberg-Universität Mainz |
3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
|
EP2343291A1
(en)
|
2009-12-18 |
2011-07-13 |
Johannes Gutenberg-Universität Mainz |
3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
EP2474541A1
(en)
|
2010-12-23 |
2012-07-11 |
Johannes- Gutenberg-Universität Mainz |
Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
GB201111427D0
(en)
*
|
2011-07-05 |
2011-08-17 |
Amakem Nv |
Novel bisindolylmaleimides, pan-pkc inhibitors
|
CA2892927A1
(en)
*
|
2012-12-10 |
2014-06-19 |
Centogene Ag |
Use of maleimide derivatives for preventing and treating leukemia
|
CA2892921A1
(en)
*
|
2012-12-10 |
2014-06-19 |
Centogene Ag |
Use of maleimide derivatives for preventing and treating cancer
|
CN103382199A
(zh)
*
|
2013-06-28 |
2013-11-06 |
北京理工大学 |
一种n-烷基-双吲哚马来酰亚胺的制备方法
|
JP2017524739A
(ja)
|
2014-07-17 |
2017-08-31 |
アンセルムInserm |
神経筋接合部関連疾患の処置方法
|
WO2016207366A1
(en)
|
2015-06-26 |
2016-12-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of viral infections
|
EP3187495A1
(en)
|
2015-12-30 |
2017-07-05 |
Johannes Gutenberg-Universität Mainz |
3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
|
CN105777751B
(zh)
*
|
2016-04-26 |
2018-12-11 |
浙江工业大学 |
一种双芳基马来酰亚胺类化合物及其药学上可接受的盐及其制备方法和应用
|
US20230203017A1
(en)
*
|
2021-12-28 |
2023-06-29 |
Kamal D. Mehta |
Protein Kinase C Beta Inhibitors and Uses Thereof
|